文献速递神经肿瘤

ZEB1缺失增加胶质瘤干细胞致瘤性并导致放化疗抵抗

ZEB1 loss increases glioma stem cell tumorigenicity and resistance to chemoradiation.
PubMed 文献 · J Neurosurg · 2022-09-16

该研究探讨转录因子ZEB1在胶质母细胞瘤治疗抵抗中的作用。ZEB1缺失患者生存期短于野生型,ZEB1敲低胶质瘤干细胞小鼠生存期缩短;ZEB1缺失干细胞增殖侵袭增强,对化疗、放疗及联合放化疗抵抗增强,可能通过HER3/Akt通路上调HER3;过表达ZEB1则增加放化疗敏感性。

要点

  • ZEB1缺失患者在高、低MGMT组中生存期均短于野生型ZEB1患者。
  • ZEB1敲低胶质瘤干细胞移植小鼠生存期短于非沉默对照shRNA移植小鼠。
  • ZEB1缺失干细胞对化疗、放疗及联合放化疗抵抗增强,过表达则敏感性增加。

核心结论

  • 癌症干细胞中ZEB1缺失导致放化疗抵抗,并揭示这些抵抗细胞中一个潜在可靶向的细胞表面受体。

研究设计与样本

  • 研究在胶质瘤干细胞和患者数据中探索ZEB1缺失与过表达背景下的治疗抵抗。
  • 使用ZEB1敲低胶质瘤干细胞移植小鼠与非沉默对照shRNA胶质瘤干细胞移植小鼠比较生存期。

主要发现

  • ZEB1缺失患者在高MGMT组和低MGMT组中生存期均短于野生型ZEB1患者。
  • ZEB1敲低胶质瘤干细胞移植小鼠生存期短于非沉默对照shRNA胶质瘤干细胞移植小鼠。
  • ZEB1缺失胶质瘤干细胞增殖和侵袭致瘤性增加。
  • 失去ZEB1表达的胶质瘤干细胞对化疗、放疗及联合放化疗抵抗增强。
  • ZEB1缺失可能通过HER3/Akt通路上调HER3表达而与化疗抵抗相关;ZEB1缺失干细胞中过表达ZEB1增加放化疗敏感性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Glioblastoma has been known to be resistant to chemotherapy and radiation, whereas the underlying mechanisms of resistance have not been fully elucidated. The authors studied the role of the transcription factor ZEB1 (zinc finger E-box-binding homeobox 1 protein), which is associated with epithelial-mesenchymal transition (EMT) and is central to the stemness of glioblastoma, to determine its role in therapeutic resistance to radiation and chemotherapy. The authors previously demonstrated that ZEB1 is deleted in a majority of glioblastomas. METHODS: The authors explored resistance to therapy in the context of ZEB1 loss and overexpression in glioma stem cells (GSCs) and in patient data. RESULTS: Patients with ZEB1 loss had a shorter survival time than patients with wild-type ZEB1 in both the high- and low-MGMT groups. Consistent with the clinical data, mice implanted with ZEB1 knockdown GSCs showed shortened survival compared with mice inoculated with nonsilencing control (NS) short-hairpin RNA (shRNA) GSC glioblastoma. ZEB1-deleted GSCs demonstrated increased tumorigenicity with regard to proliferation and invasion. Importantly, GSCs that lose ZEB1 expression develop enhanced resistance to chemotherapy, radiotherapy, and combined chemoradiation. ZEB1 loss may lead to increased HER3 expression through the HER3/Akt pathway associated with this chemoresistance. Conversely, overexpression of ZEB1 in GSCs that are ZEB1 null leads to increased sensitivity to chemoradiation. CONCLUSIONS: The study results indicate that ZEB1 loss in cancer stem cells confers resistance to chemoradiation and uncovers a potentially targetable cell surface receptor in these resistant cells.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Hanna GK, Madany M, Tay ASS, et al. ZEB1 loss increases glioma stem cell tumorigenicity and resistance to chemoradiation. J Neurosurg. 2022. PMID: 36115050. doi:10.3171/2022.7.JNS22259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。